All In Biotech

Free tool

FAERS Monitor: Ziihera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761416 or its brand name (Ziihera, Zanidatamab-Hrii). Reports on generic versions are filed under their own applications.

Reports

82

Serious

37

45% of reports

Hospitalization

7

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use23
  • infusion related reaction11
  • diarrhoea10
  • chills9
  • pyrexia6
  • ejection fraction decreased4
  • hyperpyrexia3
  • acute kidney injury2
  • arthralgia2
  • disease progression2
  • drug ineffective2
  • gastrointestinal haemorrhage2
  • hypersensitivity2
  • oxygen saturation decreased2
  • platelet count decreased2

Reports by year received

View as table
YearReports
202535
202647

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,077 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperpyrexiaSignal3181.959.9374
ejection fraction decreasedSignal466.025.4195
infusion related reactionSignal1142.624.6407
chillsSignal919.710.6142
oxygen saturation decreased29.12.38
off label useSignal236.74.8111
gastrointestinal haemorrhage26.11.64
platelet count decreased24.81.23
pyrexiaSignal64.42.113
disease progression24.31.12
diarrhoeaSignal104.02.220
acute kidney injury23.40.91
hypersensitivity22.80.71
arthralgia21.20.30
drug ineffective20.40.11

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.